Cyclacel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Bio Green Med Solution

09/08/2023 21:56

* Cyclacel Pharmaceuticals Inc  CYCC.OQ  reported a
quarterly
adjusted loss of 44 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 50 cents per share.
    * Revenue was $373.00 thousand​; analysts expected zero. 
    * The mean earnings estimate of analysts had risen by
about 7.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cyclacel Pharmaceuticals Inc shares had fallen by 0.7%
this
quarter and lost 12.3% so far this year.
    * The company reported a quarterly loss of $5.5 million.
    * Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $13.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 08:55 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.50          -0.44          Beat
 Mar. 31 2023      -0.66          -0.47          Beat
 Dec. 31 2022      -0.48          -0.60          Missed
 Sep. 30 2022      -0.56          -0.42          Beat